目前,恶性肿瘤仍是全球范围内人类疾病死亡的主要原因之一。越来越多的研究揭示,恶性肿瘤的发生进展与基因表达密切相关。因此,通过转录组学研究寻找恶性肿瘤相关的生物标志物已成为癌症研究的热门领域。白细胞免疫球蛋白样受体B家族成...目前,恶性肿瘤仍是全球范围内人类疾病死亡的主要原因之一。越来越多的研究揭示,恶性肿瘤的发生进展与基因表达密切相关。因此,通过转录组学研究寻找恶性肿瘤相关的生物标志物已成为癌症研究的热门领域。白细胞免疫球蛋白样受体B家族成员3 (Leukocyte immunoglobulin-like receptor subfamily B member 3, LILRB3)是LILR家族的一员,在免疫细胞中广泛表达,主要抑制免疫反应并介导耐受。LILRB3的异常表达与一系列病理学过程相关,包括感染和肿瘤进展过程中的免疫功能抑制,这表明LILRB3可能是免疫疗法的潜在候选靶点。本综述将概述这一广泛的免疫受体的免疫学功能和肿瘤相关性,总结了其在急性髓系白血病白血病、结直肠癌、神经胶质瘤等肿瘤中的研究进展,希望能够为靶向LILR治疗从癌症到自身免疫等多种疾病研究提供新的思路。Currently, malignant tumors remain one of the principal causes of mortality from human diseases globally. An increasing body of research has unveiled that the genesis and progression of malignant tumors are intimately associated with gene expression. Consequently, the quest for biomarkers related to malignant tumors through transcriptomic studies has emerged as a fervent area of cancer research. The Leukocyte immunoglobulin-like receptor subfamily B member 3 (LILRB3), a constituent of the LILR family, is ubiquitously expressed in immune cells, primarily inhibiting immune responses and mediating tolerance. The aberrant expression of LILRB3 is linked with a spectrum of pathological processes, including the suppression of immune function during infections and tumor progression, suggesting LILRB3 as a potential target for immunotherapy. This review aims to encapsulate the immunological functions and tumor relevance of this expansive immune receptor, summarizing its research progress in malignancies such as acute myeloid leukemia, colorectal cancer, and glioma, in hopes of furnishing novel insights for targeted LILR therapy in a wide array of diseases ranging from cancer to autoimmunity.展开更多
文摘目前,恶性肿瘤仍是全球范围内人类疾病死亡的主要原因之一。越来越多的研究揭示,恶性肿瘤的发生进展与基因表达密切相关。因此,通过转录组学研究寻找恶性肿瘤相关的生物标志物已成为癌症研究的热门领域。白细胞免疫球蛋白样受体B家族成员3 (Leukocyte immunoglobulin-like receptor subfamily B member 3, LILRB3)是LILR家族的一员,在免疫细胞中广泛表达,主要抑制免疫反应并介导耐受。LILRB3的异常表达与一系列病理学过程相关,包括感染和肿瘤进展过程中的免疫功能抑制,这表明LILRB3可能是免疫疗法的潜在候选靶点。本综述将概述这一广泛的免疫受体的免疫学功能和肿瘤相关性,总结了其在急性髓系白血病白血病、结直肠癌、神经胶质瘤等肿瘤中的研究进展,希望能够为靶向LILR治疗从癌症到自身免疫等多种疾病研究提供新的思路。Currently, malignant tumors remain one of the principal causes of mortality from human diseases globally. An increasing body of research has unveiled that the genesis and progression of malignant tumors are intimately associated with gene expression. Consequently, the quest for biomarkers related to malignant tumors through transcriptomic studies has emerged as a fervent area of cancer research. The Leukocyte immunoglobulin-like receptor subfamily B member 3 (LILRB3), a constituent of the LILR family, is ubiquitously expressed in immune cells, primarily inhibiting immune responses and mediating tolerance. The aberrant expression of LILRB3 is linked with a spectrum of pathological processes, including the suppression of immune function during infections and tumor progression, suggesting LILRB3 as a potential target for immunotherapy. This review aims to encapsulate the immunological functions and tumor relevance of this expansive immune receptor, summarizing its research progress in malignancies such as acute myeloid leukemia, colorectal cancer, and glioma, in hopes of furnishing novel insights for targeted LILR therapy in a wide array of diseases ranging from cancer to autoimmunity.
